About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Purinergic Compounds in Pseudoxanthoma Elasticum | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT07323082

Purinergic Compounds in Pseudoxanthoma Elasticum

Pseudoxanthoma elasticum (PXE) is a rare genetic disorder, transmitted as an autosomal recessive trait, affecting approximately 1 in 50,000 people, predominantly women. It is characterised by progress...

Lead sponsor: Centre Hospitalier Universitaire de Nice•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Georges LEFTHERIOTIS, PUPH

CONTACT

04 92 03 85 48 leftheriotis.g@chu-nice.fr

Luc Froissant

CONTACT

04 92 03 85 48 froissant.l@chu-nice.fr

Sponsors

Lead Sponsor

Centre Hospitalier Universitaire de Nice

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male or female,
•Age \>18 years
•Covered by social security,
•Informed and having signed the informed consent form.
•PXE patients:
•\- with PXE defined according to current clinical criteria for PXE (REACT-PXE and PNDS consensus) and with an ABCC6 mutation.

Exclusion Criteria

•Patients treated with bisphosphonates, vitamin K antagonists, and dietary supplements containing calcium, phosphates, magnesium, zinc, or iron.
•Treatments likely to alter adenosine levels (caffeine, salbutamol, beta-blockers, etc.).
•Progressive bone diseases (osteoporosis, chondrocalcinosis, gout, etc.).
•Progressive and/or treated cancerous diseases.
•Progressive and/or treated inflammatory or autoimmune diseases.

Related studies

Progression Assessment of PXE-associated Alterations

NCT07048106 · Pseudoxanthoma Elasticum, Angioid Streaks, and more

Active Not Recruiting

Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration

NCT05662085 · Pseudoxanthoma Elasticum

COMPLETEDPhase 2

A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

NCT05569252 · Pseudoxanthoma Elasticum

Employment of Patients With Pseudoxanthoma Elasticum

NCT05246189 · Pseudoxanthoma Elasticum, Employment

WITHDRAWNPhase 2

Oral Pyrophosphate Absorption in PXE Disease

NCT04441671 · Pseudoxanthoma Elasticum

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 24, 2026Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment45

Start dateJan 2026

Last updatedApr 24, 2026

Condition

Pseudoxanthoma Elasticum

Locations shown

Angers University hospital

Angers

Nice University hospital

Nice

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 24, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions